Liquidia Co. (NASDAQ:LQDA – Get Free Report) CEO Roger Jeffs sold 8,360 shares of Liquidia stock in a transaction on Friday, April 12th. The stock was sold at an average price of $14.58, for a total value of $121,888.80. Following the transaction, the chief executive officer now directly owns 826,985 shares of the company’s stock, valued at approximately $12,057,441.30. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Roger Jeffs also recently made the following trade(s):
- On Monday, March 18th, Roger Jeffs sold 28,583 shares of Liquidia stock. The stock was sold at an average price of $15.82, for a total value of $452,183.06.
Liquidia Stock Up 2.1 %
NASDAQ LQDA opened at $13.86 on Thursday. Liquidia Co. has a 12 month low of $5.71 and a 12 month high of $16.99. The company has a 50-day moving average of $14.75 and a 200-day moving average of $10.95.
Analysts Set New Price Targets
Several research analysts have recently issued reports on LQDA shares. LADENBURG THALM/SH SH lifted their price target on Liquidia from $15.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, December 21st. Bank of America lifted their price target on Liquidia from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, December 21st. Needham & Company LLC restated a “buy” rating and issued a $28.00 target price on shares of Liquidia in a report on Wednesday, April 10th. HC Wainwright upped their target price on shares of Liquidia from $16.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, March 14th. Finally, Wedbush restated an “underperform” rating and issued a $3.00 target price on shares of Liquidia in a report on Thursday, December 21st. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $21.00.
Institutional Trading of Liquidia
A number of institutional investors and hedge funds have recently bought and sold shares of LQDA. Fortitude Family Office LLC acquired a new stake in Liquidia during the 4th quarter worth approximately $26,000. UBS Group AG increased its position in Liquidia by 134.0% during the 2nd quarter. UBS Group AG now owns 7,948 shares of the company’s stock worth $35,000 after purchasing an additional 4,552 shares in the last quarter. Legal & General Group Plc acquired a new stake in Liquidia during the 2nd quarter worth approximately $38,000. BNP Paribas Arbitrage SA increased its position in Liquidia by 42.8% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 10,682 shares of the company’s stock worth $47,000 after purchasing an additional 3,200 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its position in Liquidia by 101.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,004 shares of the company’s stock worth $55,000 after purchasing an additional 3,524 shares in the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.
Liquidia Company Profile
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Featured Articles
- Five stocks we like better than Liquidia
- What Investors Need to Know to Beat the Market
- United Airlines Soars on Earnings Beat
- What Are the FAANG Stocks and Are They Good Investments?
- J.B. Hunt Hits the Skids: Lower Prices to Come
- What is the Shanghai Stock Exchange Composite Index?
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.